FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
Bad news for Pfizer as blockbuster Xeljanz flunks safety studyJAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and Share XBad news for Pfizer as blockbuster Xeljanz flunks safety studyhttps://pharmaphorum.com/news/bad-news-for-pfizer-as-blockbuster-xeljanz-flunks-safety-study/
AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
AbbVie begins trials of COVID-19 antibody therapyAbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the Share XAbbVie begins trials of COVID-19 antibody therapyhttps://pharmaphorum.com/news/abbvie-licenses-in-covid-19-antibody-therapy-from-harbour-utrecht-uni/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
NICE backs chemo-free CLL combination from AbbVie and RochePreviously untreated patients with chronic lymphocytic leukaemia (CLL) in England will get a chemotherapy-free treatment option after NICE Share XNICE backs chemo-free CLL combination from AbbVie and Rochehttps://pharmaphorum.com/news/nice-backs-chemo-free-cll-combination-from-abbvie-and-roche/
FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapiesCombination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute Share XFDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapieshttps://pharmaphorum.com/news/fda-grants-full-approval-for-roche-abbvies-venclexta-in-aml-combination-therapies/
